In gastrointestinal cancers, dabrafenib and trametinib have shown remarkable results in biliary tract cancers (BTC), establishing this combination as a viable second-line option for <i>BRAF</i> <sup>V600E</sup>-mutant BTC. This evidence concerns the gene BRAF and biliary tract neoplasm.